FEMY Stock Overview
A biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Femasys Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.15 |
| 52 Week High | US$1.80 |
| 52 Week Low | US$0.86 |
| Beta | -2.52 |
| 1 Month Change | 2.68% |
| 3 Month Change | -2.54% |
| 1 Year Change | -9.45% |
| 3 Year Change | -22.30% |
| 5 Year Change | n/a |
| Change since IPO | -90.42% |
Recent News & Updates
Recent updates
Is Femasys (NASDAQ:FEMY) Using Debt In A Risky Way?
Feb 16
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry?
Oct 31Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now
Jul 05Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?
Apr 03Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation
Sep 27Femasys commercially launches Femcerv for cervical cancer screening
Sep 29Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M
Aug 10We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully
May 22Femasys: Revolutionizing Female Reproduction
Jul 16Shareholder Returns
| FEMY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.7% | 2.0% | 1.3% |
| 1Y | -9.4% | 7.9% | 8.2% |
Return vs Industry: FEMY underperformed the US Medical Equipment industry which returned 8.8% over the past year.
Return vs Market: FEMY underperformed the US Market which returned 7.7% over the past year.
Price Volatility
| FEMY volatility | |
|---|---|
| FEMY Average Weekly Movement | 11.2% |
| Medical Equipment Industry Average Movement | 9.6% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: FEMY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FEMY's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 70 | Kathy Lee-Sepsick | www.femasys.com |
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution.
Femasys Inc. Fundamentals Summary
| FEMY fundamental statistics | |
|---|---|
| Market cap | US$30.95m |
| Earnings (TTM) | -US$18.82m |
| Revenue (TTM) | US$1.63m |
19.2x
P/S Ratio-1.7x
P/E RatioIs FEMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FEMY income statement (TTM) | |
|---|---|
| Revenue | US$1.63m |
| Cost of Revenue | US$544.90k |
| Gross Profit | US$1.08m |
| Other Expenses | US$19.90m |
| Earnings | -US$18.82m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 66.55% |
| Net Profit Margin | -1,155.03% |
| Debt/Equity Ratio | 234.6% |
How did FEMY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 06:05 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Femasys Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |
| Catherine Novack | JonesTrading Institutional Services, LLC |